- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
AHA Guidelines on Obesity for CVD Prevention: 5 Questions
Obesity is a primary risk factor for cardiovascular disease and can also be modified with comprehensive care. Test yourself on the AHA/ACC recommendations for that care.
FOCUS: Preventive Cardiology and Obesity
Obesity is a risk factor for nearly all forms of cardiovascular and cardiometabolic disease. In fact, the epidemic status of obesity in the United States has been identified as responsible for the rise in deaths from heart disease after 4 decades of steady decline.
Prevention and management of overweight and obesity is central to primary prevention of CVD. Test yourself on the most recent guidance from the American Heart Association/American College of Cardiology (AHA/ACC) on comprehensive interventions to treat patients with this chronic, relapsing disease.
Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial
August 26th 2025Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.
